ArticleGastro hep advances2025
Pharmacotherapy for Alcohol Use Disorder Is Underutilized Among Commercially Insured Adults With Alcohol-Associated Liver Disease.
Article in Gastro hep advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Limited but Growing Use of Medications for Alcohol Use Disorder by Gastroenterologists: A Medicare Analysis, 2016-2024.Gastro hep advances · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Background and Aims: Alcohol use disorder (AUD) pharmacotherapy reduces hepatic decompensation and mortality in patients with alcohol-associated liver disease (ALD). We aimed to characterize the use of AUD pharmacotherapy in a large national cohort. Methods: Adults with AUD were identified in PharMetrics Plus for Academics-a nationally representative claims database of commercially insured Americans. We examined receipt of AUD therapy and associated treatment patterns. Results: A total of 28,625 patients with AUD were identified: 1640 (5.7%) had ALD, among whom 439 (1.5%) had acute alcohol-associated hepatitis (AAH). Pharmacotherapy was prescribed in 14.5% of patients without ALD, 2.3% with ALD cirrhosis, and 9.8% with AAH. The most prescribed medication was gabapentin (9.4%). Among those receiving pharmacotherapy, one-time prescriptions were observed in 28.4% of patients without ALD, 10.7% with ALD cirrhosis, and 18.6% with AAH. The median time from diagnosis to receipt of pharmacotherapy was 10 months (interquartile range [IQR] 1.5-29.2). On regression analysis, nonsubstance use psychiatric diagnosis (adjusted odds ratio [aOR]: 2.71; 95% confidence interval [CI] [2.51, 2.93]) and female sex (aOR: 1.32; 95% CI [1.22, 1.42]) were associated with receipt of pharmacotherapy, while ALD cirrhosis (aOR: 0.22; 95% CI [0.14, 0.32]) and hepatic decompensation (aOR: 0.07; 95% CI [0.02, 0.16]) were associated with not receiving pharmacotherapy. Conclusion: AUD pharmacotherapy appeared underutilized in a large cohort of commercially insured U.S. adults, particularly among patients with ALD and hepatic decompensation. Providers caring for patients with AUD across the spectrum of liver disease should be aware of potential underutilization of these medications, especially among males and patients with cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.